<br />
DERMATOLOGY<br />
EMJ Dermatol. 2019 Suppl 7 • europeanmedical-journal.com<br />
INSIDE<br />
IL-23 Inhibition in Psoriasis:<br />
A Novel Approach to Convenient,<br />
Consistent Clearance<br />
IL-23 Inhibition in Psoriasis: A Novel Approach<br />
to Convenient, Consistent Clearance<br />
This sponsored symposium took place on 12th June 2019 in Milan, Italy,<br />
as part of the 24th World Congress of Dermatology (WCD), 2019<br />
Chairperson: Kristian Reich¹<br />
Speakers: Bruce Strober,2 Curdin Conrad3<br />
1. Institute for Health Services Research in Dermatology and Nursing, University<br />
Medical Center Hamburg-Eppendorf, and Skin Inflammation® Center, Hamburg,<br />
Germany<br />
2. Yale University School of Medicine, New Haven, Connecticut, USA<br />
3. University Hospital of Lausanne, Lausanne, Switzerland<br />
Disclosure: Prof Reich has been an advisor and/or paid speaker and/or participa<a title="EMJ Dermatol. 2019 Suppl 7 page 1" href="http://viewer.zmags.com/publication/8ddf97ab?page=1"> DERMATOLOGY EMJ Dermatol. 2019 Suppl 7 • european</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 2" href="http://viewer.zmags.com/publication/8ddf97ab?page=2"> IL-23 Inhibition in Psoriasis: A Novel Approach </a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 3" href="http://viewer.zmags.com/publication/8ddf97ab?page=3"> and IMMvent for risankizumab. Taken together, the</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 4" href="http://viewer.zmags.com/publication/8ddf97ab?page=4"> leads to exacerbation of IBD. This unexpected cli</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 5" href="http://viewer.zmags.com/publication/8ddf97ab?page=5"> Patients responding to guselkumab at Week 20 were</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 6" href="http://viewer.zmags.com/publication/8ddf97ab?page=6"> PASI 75 response. By Week 28, 74% patients on eit</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 7" href="http://viewer.zmags.com/publication/8ddf97ab?page=7"> Patient Profiling in Daily Practice: Which Drug </a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 8" href="http://viewer.zmags.com/publication/8ddf97ab?page=8"> Table 1: Treatment choices in psoriasis with como</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 9" href="http://viewer.zmags.com/publication/8ddf97ab?page=9"> of HBV infections, whereas HBV reactivation has b</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 10" href="http://viewer.zmags.com/publication/8ddf97ab?page=10"> taltz-epar-product- information_ en.pdf. Last acc</a>
<a title="EMJ Dermatol. 2019 Suppl 7 page 11" href="http://viewer.zmags.com/publication/8ddf97ab?page=11"> 40. Yiu ZZN et al. Risk of serious infec</a>